What should you know about LCIS pathology outlines?

Lobular carcinoma in situ, or LCIS, is a finding in which cells fill or expand the milk-producing lobules without breaking through into surrounding breast tissue. It is usually found from a biopsy performed for another breast change, rather than from a visible symptom. A report may mention classic LCIS, pleomorphic LCIS, the amount of tissue involved, and whether the sample adequately explains the imaging finding. These details help the breast specialist decide whether more tissue should be examined.

LCIS is not the same as invasive breast cancer, but it signals a higher future risk of breast cancer in either breast. The wording alone cannot determine an individual's personal outlook; age, family history, imaging, biopsy method, and other findings are considered together.

Arrange a review with the clinician who performed the biopsy or a breast specialist. Ask whether the pathology and imaging agree, whether the biopsy removed the area of concern, and whether a surgical excision is being considered. Your plan may include regular clinical review and breast imaging tailored to your risk profile. Some people discuss risk-reducing endocrine therapy, which can lower the chance of certain hormone-sensitive breast cancers but also has possible side effects.

Keep a copy of the pathology report and note any family history of breast or ovarian cancer. Do not start or stop a hormone medicine without discussing your medical history and other medicines with the prescriber.

Contact your breast clinic promptly if a new lump, nipple inversion, bloody discharge, skin dimpling, or persistent one-sided breast change appears. After a biopsy, seek urgent medical advice for rapidly increasing swelling, fever, spreading redness, heavy bleeding, or worsening pain. These symptoms need assessment because they may reflect a breast problem or a procedure-related complication; they do not by themselves establish cancer.

Which type of LCIS is described, and does it match the imaging? Do I need more tissue removed? What surveillance schedule fits my risk? Would risk-reducing endocrine therapy suit me? Which breast changes should I report between appointments?